Pyxis Oncology (NASDAQ:PYXS) Receives Buy Rating from HC Wainwright

Pyxis Oncology (NASDAQ:PYXS)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They currently have a $5.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 313.22% from the stock’s current price.

Separately, Royal Bank of Canada restated an “outperform” rating and issued a $8.00 target price on shares of Pyxis Oncology in a research note on Wednesday, March 19th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $9.00.

Pyxis Oncology Trading Up 9.0%

Shares of Pyxis Oncology stock opened at $1.21 on Monday. The stock has a market capitalization of $74.96 million, a price-to-earnings ratio of -1.17 and a beta of 1.15. The firm’s 50-day moving average price is $1.05 and its two-hundred day moving average price is $1.62. Pyxis Oncology has a 1-year low of $0.83 and a 1-year high of $5.39.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.06). As a group, equities research analysts predict that Pyxis Oncology will post -1.04 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of PYXS. ProShare Advisors LLC bought a new position in Pyxis Oncology in the 4th quarter valued at $26,000. Caption Management LLC acquired a new position in shares of Pyxis Oncology during the fourth quarter valued at $35,000. Ameriprise Financial Inc. acquired a new position in shares of Pyxis Oncology during the fourth quarter valued at $35,000. Commonwealth Equity Services LLC boosted its holdings in Pyxis Oncology by 61.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company’s stock valued at $41,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Graham Capital Management L.P. acquired a new stake in Pyxis Oncology in the fourth quarter worth about $47,000. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.